Prof. Dr. rer. nat. Claus Scheidereit
Signal Transduction in Tumor Cells
Coordinator of the MDC Cancer Research Program
Max-Delbrück Center for Molecular Medicine (MDC)
Robert-Rössle-Str. 10
13092 Berlin
Tel: +49 30 9406 3816
E-Mail: scheidereit(at)mdc-berlin.de
https://www.mdc-berlin.de/scheidereit
University Education
- 1982 Diploma in Chemistry, Universität Marburg
- 1984 Dr. rer. nat., Universität Marburg (with honours)
Professional Experience (selection)
- 1984-1985 Postdoctoral fellow, Universität Marburg
- 1986-1988 Postdoctoral fellow, Rockefeller University, USA
- 1989-1994 Independent research group leader, MPI for Melecular Genetics, Berlin
- 1994- Research group leader, MDC
- Coordinator of the MDC Cancer Research Program
Research
Our laboratory is interested in signal transduction processes that activate the inducible transcription factor nuclear factor-κB (NF-κB) as well as in regulatory mechanisms that control the activity of NF-κB in the nucleus.
NF-κB and its regulators provide an excellent model system with broad physiological and medical significance. The transcription factor controls important steps in immunity and inflammation, as well as cell death, proliferation or metabolism. Its activity is controlled by inhibitory IκB proteins and the IκB kinase (IKK) complex.
We wish to decipher mechanisms that underlie gene regulation by IKK and NF-κB in development and diseases. To reach these goals, we are utilizing a wide variety of approaches, including classical biochemistry, mouse-models, 3D optical imaging, systems biology, genome-wide target gene determination and siRNA screening as well as mass spectrometry (MS)-based proteomics.
Most important Awards, Grants or Scientific Achievements
- 2005 German Cancer Prize, Deutsche Krebsgesellschaft e.V.
- Member of the Advisory Editorial Board, EMBO Reports
Selected References
- Kolesnichenko, M., Mikuda, N., Höpken, U.E., Milanovic, M., Tufan, A.B., Uyar, B, Sun, W., Schleich, K., von Hoff, L., Willenbrock, W., Krahn, I., Jungmann, S., Hinz, M., Akalin, A., Lee, S., Schmidt-Ullrich, R., Schmitt, C.A., and Scheidereit, C. (2021) "IKK- and proteasome-independent RelA activation triggers SASP in senescence via NFKBIA silencing." EMBO J. Jan 18:e104296.
- von Hoff, L., Kaergel, E., Franke, V., McShane, E., Schulz-Beiss, K.W., Patone, G., Schleussner, N., Kolesnichenko, M., Hübner, N., Daumke, O., Selbach, M., Akalin, A., Mathas, S. and Scheidereit, C. (2019) "Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma." Blood 133:1489-1494.
- Mikuda, N., Kolesnichenko, M., Beaudette, P., Popp, O., Uyar, B., Sun, W., Tufan, A.B., Perder, B., Alkalin, A., Chen, W., Mertins, P., Dittmar, G., Hinz, M., and Scheidereit, C. (2018) "The IκB kinase complex is a regulator of mRNA stability." EMBO J. 2018 Dec 14. 37: e98658.
- de Olivera, K.P., Kaergel, E., Heinig, M., Lafontaine, J.F., Patone, G., Muro, E.M., Mathas, S., Hummel, M., Andrade, M. Hübner, N, and Scheidereit, C. (2016) "A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses." Genome Medicine 8:28.
- Hinz, M., Stilmann, M., Çöl Arslan, S., Khanna, K.K., Dittmar, G., and Scheidereit, C. (2010) "A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation." Mol Cell 40, 63-74.